Physician profile
Kayla M Corell
NPI 1306428230
$675.23
in general payments reported to CMS, 2019-2025
15 companies · $70.33 in 2025
The $70.33 reported for 2025 was less than what a typical Registered Nurse provider received nationally (typical 2025 total: $73.55).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $24.46 · 2022: $187 · 2023: $225 · 2024: $169 · 2025: $70.33.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $464.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $463.74 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Lilly USA, LLC | $166.85 | 2022-2025 | Mounjaro, Jardiance, Emgality |
| Amgen INC. | $91.16 | 2021-2025 | Repatha, Otezla |
| Abbvie INC. | $74.58 | 2022-2024 | |
| Ferring Pharmaceuticals INC. | $71.14 | 2023 | Rebyota |
| Novo Nordisk INC | $44.86 | 2022-2024 | Wegovy |
| Exact Sciences Corporation | $40.16 | 2023-2024 | Cologuard Collection Kit |
| Bayer Healthcare Pharmaceuticals INC. | $32.50 | 2023-2024 | |
| Dexcom, INC. | $30.92 | 2023 | Dexcom G6 Transmitter |
| Alkermes, INC. | $25.55 | 2025 | Vivitrol |
| Idorsia Pharmaceuticals US INC | $20.61 | 2023 | Quviviq |
| Janssen Pharmaceuticals, INC | $19.64 | 2022 | |
| Lundbeck LLC | $18.69 | 2024 | Rexulti |
| Astrazeneca Pharmaceuticals LP | $17.06 | 2024 | Airsupra |
| Pfizer INC. | $15.02 | 2024 | |
| Genentech USA, INC. | $6.49 | 2021 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Kayla Corell listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.